© 2002 by European Society of Cardiology
Copyright © 2002, European Society of Cardiology
p38 MAP kinase is a mediator of ischemic preconditioning in pigs
aAbteilungen für Pathophysiologie, Zentrum für Innere Medizin, Universitätsklinikum Essen, Hufelandstrasse 55, 45122 Essen, Germany
bNieren- und Hochdruckkrankheiten, Zentrum für Innere Medizin Universitätsklinikum Essen, 45122 Essen, Germany
gerd.heusch{at}uni-essen.de
* Corresponding author. Tel.: +49-201-723-4480; fax: +49-201-723-4481
Objective: The role of p38MAPK in ischemic preconditioning (IP) is still equivocal, insofar as the p38MAPK-inhibitor SB203580 abolished IP in rats, rabbits and dogs, but not in pigs. Blockade of p38MAPK prior to the sustained ischemia also generated contradictory findings, insofar as p38MAPK acted as trigger in dogs but as mediator in rats. We have now tested whether the two structurally unrelated p38MAPK-inhibitors, BIX-645 and SB203580, abolished infarct size (IS) reduction by IP in pigs and whether their effects depended on the time of administration. Methods: Sixty-five enflurane-anesthetized pigs underwent 90 min low-flow ischemia and 120 min reperfusion without or with one preceding cycle of 10 min preconditioning ischemia and 15 min reperfusion. Pigs received BIX-645 (1 mg/kg, i.v.) or SB203580 (10 µM, i.c.) prior to either IP or the sustained ischemia. Results: IS (% TTC-staining) was reduced by IP [4.8±3.1(S.E.M.), P<0.05] compared to placebo (25.8±5.5). BIX-645 or SB203580 per se had no effect on IS (23.5±5.2 and 21.8±4.4, respectively). IS reduction by IP was abolished by BIX-645 (26.2±6.4 or 25.5±4.7) and SB203580 (19.9±4.3 or 16.7±4.7), given either prior to IP or the sustained ischemia, respectively. The supernatant of homogenized myocardial biopsies taken during the sustained ischemia from preconditioned pigs receiving either BIX-645 or SB203580 inhibited the anisomycin-stimulated ATF-2 phosphorylation in cultured Rat1 fibroblasts. This in vitro inhibition of ATF-2 phosphorylation correlated to the actual IS. Conclusion: The attenuation of the IS-reducing effect of IP depends on the effectiveness of blockade of p38MAPK activity. p38MAPK is a mediator of IP in pigs.
KEYWORDS Ischemia; Preconditioning; Reperfusion; Signal transduction
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
N. Suleman, S. Somers, R. Smith, L. H. Opie, and S. C. Lecour Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning Cardiovasc Res, July 1, 2008; 79(1): 127 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Roesslein, M. Frick, V. Auwaerter, M. Humar, U. Goebel, C. Schwer, K. K. Geiger, H. L. Pahl, B. H. J. Pannen, and T. Loop Sevoflurane-Mediated Activation of p38-Mitogen-Activated Stresskinase is Independent of Apoptosis in Jurkat T-Cells Anesth. Analg., April 1, 2008; 106(4): 1150 - 1160. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Heidbreder, A. Naumann, K. Tempel, P. Dominiak, and A. Dendorfer Remote vs. ischaemic preconditioning: the differential role of mitogen-activated protein kinase pathways Cardiovasc Res, April 1, 2008; 78(1): 108 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Zhao, G. Cheng, L. X. Zhang, Y. T. Tseng, and J. F. Padbury Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury Cardiovasc Res, December 1, 2007; 76(3): 473 - 481. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-J. Xu, H. K. Saini, M. Zhang, V. Elimban, and N. S. Dhalla MAPK activation and apoptotic alterations in hearts subjected to calcium paradox are attenuated by taurine Cardiovasc Res, October 1, 2006; 72(1): 163 - 174. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Kaiser, J. M. Lyons, J. Y. Duffy, C. J. Wagner, K. M. McLean, T. P. O'Neill, J. M. Pearl, and J. D. Molkentin Inhibition of p38 reduces myocardial infarction injury in the mouse but not pig after ischemia-reperfusion Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2747 - H2751. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ballard-Croft, G. Kristo, Y. Yoshimura, E. Reid, B. J. Keith, R. M. Mentzer Jr., and R. D. Lasley Acute adenosine preconditioning is mediated by p38 MAPK activation in discrete subcellular compartments Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1359 - H1366. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nakamura, T. Miura, A. Nakano, Y. Ichikawa, T. Yano, H. Kobayashi, Y. Ikeda, T. Miki, and K. Shimamoto Role of microtubules in ischemic preconditioning against myocardial infarction Cardiovasc Res, November 1, 2004; 64(2): 322 - 330. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Inserte, D. Garcia-Dorado, M. Ruiz-Meana, L. Agullo, P. Pina, and J. Soler-Soler Ischemic preconditioning attenuates calpain-mediated degradation of structural proteins through a protein kinase A-dependent mechanism Cardiovasc Res, October 1, 2004; 64(1): 105 - 114. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. O. McFalls, M. Hou, R. J. Bache, A. Best, D. Marx, J. Sikora, and H. B. Ward Activation of p38 MAPK and increased glucose transport in chronic hibernating swine myocardium Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1328 - H1334. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Guo, A. B. Stein, W.-J. Wu, W. Tan, X. Zhu, Q.-H. Li, B. Dawn, R. Motterlini, and R. Bolli Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1649 - H1653. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A Gorog, M. Tanno, X. Cao, M. Bellahcene, R. Bassi, A. M.N Kabir, K. Dighe, R. A Quinlan, and M. S Marber Inhibition of p38 MAPK activity fails to attenuate contractile dysfunction in a mouse model of low-flow ischemia Cardiovasc Res, January 1, 2004; 61(1): 123 - 131. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Skyschally, R. Schulz, P. Gres, H.-G. Korth, and G. Heusch Attenuation of ischemic preconditioning in pigs by scavenging of free oxyradicals with ascorbic acid Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H698 - H703. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M Yellon and J. M Downey Spotlight on preconditioning Cardiovasc Res, August 15, 2002; 55(3): 425 - 428. [Full Text] [PDF] |
||||


